Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SLAM DRILLS MORE COPPER MINERALIZATION AT GOODWIN (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Neovasc Inc. NVCN

Healthcare Medical Instruments & Supplies
Neovasc Inc is a specialty medical device company. It develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products the Neovasc Reducer (Reducer), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara, for the transcatheter... see more

Recent & Breaking News (NDAQ:NVCN)

The European Society of Cardiology Includes Neovasc Reducer™ for the Treatment of Refractory Angina in the European Practice Guidelines for the Diagnosis and Management of Chronic Coronary Syndromes

Canada NewsWire September 3, 2019

Neovasc Receives Nasdaq Notification Regarding Minimum Market Value Deficiency

Canada NewsWire August 22, 2019

Neovasc Announces Second Quarter 2019 Financial Results

Canada NewsWire August 7, 2019

Neovasc to Attend Canaccord Genuity 39th Annual Growth Conference

Canada NewsWire August 5, 2019

Neovasc to Announce Second Quarter 2019 Financial Results on Wednesday, August 7th

Canada NewsWire August 2, 2019

Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule, Resolving Last Remaining Outstanding Nasdaq Deficiency

Canada NewsWire July 17, 2019

Neovasc Provides Further Update on Reducer(TM) Program for Treatment of Refractory Angina

Canada NewsWire July 16, 2019

Neovasc Participates in Round-Robin Study Evaluating In-Vitro Pulsatile Flow Testing of Prosthetic Heart Valves

Canada NewsWire July 15, 2019

Neovasc to Explore HDE Approval Pathway and Alternate Trial Designs for the Reducer Following Guidance from the FDA

Canada NewsWire July 12, 2019

Neovasc Announces Effective Date of Share Consolidation

Canada NewsWire June 28, 2019

Neovasc Announces Presentations on Tiara(TM) for Treatment of Mitral Regurgitation and Reducer(TM) for Treatment of Refractory Angina at the CSI Frankfurt 2019 Conference

Canada NewsWire June 27, 2019

Neovasc Regains Compliance with Nasdaq Minimum Market Value Rule

Canada NewsWire June 25, 2019

Tiara(TM) Featured in Presentation at 11th Annual TVT 2019

Canada NewsWire June 17, 2019

Neovasc Announces Nasdaq Continuing to Monitor Minimum Market Value Deficiency Following 10 Consecutive Business Days Above US$35 Million

Canada NewsWire June 7, 2019

Neovasc Inc. Reports Results of Annual General and Special Meeting of Shareholders and Provides Update on Neovasc Reducer(TM)

Canada NewsWire June 4, 2019

Neovasc Announces Publication of Peer-Reviewed Article in European Heart Journal Concluding Positive Cost-Effectiveness of the Neovasc Reducer(TM)

Canada NewsWire May 28, 2019

New Tiara and Reducer Data Presented in Several Presentations at the EuroPCR 2019 Conference in Paris

Canada NewsWire May 23, 2019

Neovasc Announces Positive Two-Year Follow-up Safety and Efficacy Data for the Neovasc Reducer(TM) in a Peer Reviewed Article in the International Journal of Cardiology

Canada NewsWire May 22, 2019

Neovasc Announces Closing of Private Placement of Convertible Debt and Common Shares for Gross Proceeds of US$11.5 Million

Canada NewsWire May 16, 2019

Neovasc Announces Private Placement of Convertible Debt and Equity for Gross Proceeds of US$11.5 Million

Canada NewsWire May 14, 2019